Killer 'eye-bleeding' virus is found in France for first time

hollydolly

SF VIP
Location
London England
A disease thought to kill up to four in ten people who become infected has been identified in France for the first time.

Ticks carrying Crimean-Congo haemorrhagic fever (CCHF) have been found on the nation's border with Spain.

The disease — a cousin of Ebola — is endemic in Africa, the Middle East, Asia and the Balkans, and has been sporadically detected in southern parts of western Europe such as Spain.

Experts have long warned that climate change will propel the disease into northern Europe. And even Britain could be at risk.

77039597-12676231-image-a-19_1698334671900.jpg

Live ticks collected from cattle in the Pyrénées Orientales region were found to be harbouring the disease.

World Health Organization officials declared CCHF one of its nine priority diseases this year due to its potential threat.

CCHF is mainly spread to humans by tick bites, but people can also catch it through contact with bodily fluids from infected patients.

The disease shares similar symptoms to Ebola at the start, including muscle aches, abdominal pain, a sore throat and vomiting.

It can also trigger bleeding, usually from the nose or from broken capillaries on the eyes and skin.
Eye-bleeding virus found in FRANCE amid fears it's coming to Britain
 

just as a side supplement to your article @hollydolly:

11 September 2023
  • A new vaccine against deadly Crimean-Congo haemorrhagic fever (CCHF) is being trialled in humans for the first time.
  • The University of Oxford study aims to confirm the safety of the ChAdOx2 CCHF vaccine and investigate the development of immunity following vaccination.
  • CCHF is on the World Health Organization's top priority watchlist for viruses that could cause a future pandemic, and yet no approved vaccines currently exist.
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time.

Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.

The study is led by Professor Teresa Lambe, Principal Investigator at the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI) at the University of Oxford. Professor Lambe co-designed the Oxford/AstraZeneca COVID-19 vaccine and her team have been developing a vaccine against CCHF using similar technology for the last 5 years.

You can read the rest of the article here:
First volunteers receive vaccine for Crimean-Congo haemorrhagic fever in Oxford clinical trial
 

Back
Top